Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Tom Allinder who wrote (68478)	10/25/2000 3:47:50 PM
From: asker2	Read Replies (1) \| Respond to of 150070

DNAP news on conference... October 25, 2000 15:43 DNAPrint Presents At the 8th Annual Biopartnering Europe Conference SARASOTA, Fla.--(BUSINESS WIRE)--Oct. 20, 2000--DNAPrint genomics, Inc. (Pink Sheets:DNAP) announced today that on October 17th, Dr. Tony Frudakis, Ph.D. presented the companies business and science to an international audience of pharmaceutical executives at the recently completed 8th annual BioPartnering Europe. The conference, sponsored by the Technology Vision Group LLC was held at the Queen Elizabeth II conference center in London, England. Over 1,000 delegates attended the conference, whose major sponsors included Arthur Andersen, EASDAQ, Cooley Godward LLP, Palmer and Dodge LLP, Abbott Laboratories, AstraZeneca, BioCentury Publications, Inc, Biogen Inc., Chase H and Q, Lehman Brothers, Merck and Co, Pharmacia Corporation, Salomon Smith Barney and Smith Kline Beecham Pharmaceuticals among several others. Dr. Frudakis' presentation was well received, and resulted in the establishment of a significant number of new contacts and discussions. During the fifteen minute presentation, Dr. Frudakis outlined the company business model and advantage, highlighting the statistical and geometric informatics properties that the company is developing for associating human genetic haplotypes with complex and commercially relevant human traits. DNAP was one of only five emerging company presenters at the conference. DNAprint genomics, Inc. would like to thank the sponsors of the conference for the invitation to present. DNAPrint genomics, Inc. is developing complex genetic analytics and information resources for next generations personalized medicine. The company's products will provide practitioners of genomic research and personalized medicine with a comprehensive system for complex trait dissection and patient classification. DNAPrint genomics Inc. was founded by a group of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. For more information about the company, please visit www.DNAPrint.com All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. CONTACT: DNAPrint genomics, Inc., Sarasota Craig Hall, 941/341-0136